DGIdb - HEPARIN Drug Record

HEPARIN chembl:CHEMBL1909300

Alternate Names:

HEPARIN
HEPARINIC ACID
CALCIPARINE
HEPARIN SODIUM
HEP-LOCK
HEPARINATE
LIQUAEMIN
PANHEPRIN
SODIUM HEPARIN
chemidplus:9041-08-1
chembl:CHEMBL1909300
chemidplus:9005-49-6
drugbank:01109
pubchem.compound:22833565

Drug Info:

FDA Approval	not approved
Drug Indications	for treatment of cystic fibrosis
Drug Indications	for treatment of pelvic pain of bladder origin and interstitital cystitis
Drug Indications	antithrombotic
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	anticoagulant
Drug Categories	therapeutic uses
Drug Categories	polysaccharides
Drug Categories	pharmacologic actions
Drug Categories	molecular mechanisms of pharmacological action
Drug Categories	heparins
Drug Categories	heparin, low-molecular-weight
Drug Categories	heparin group
Drug Categories	heparin
Drug Categories	hematologic agents
Drug Categories	glycosaminoglycans
Drug Categories	fibrinolytic agents
Drug Categories	fibrin modulating agents
Drug Categories	chemical actions and uses
Drug Categories	cardiovascular agents
Drug Categories	carbohydrates
Drug Categories	blood and blood forming organs
Drug Categories	anticoagulants
Drug Groups	investigational
Drug Groups	approved
Drug Type	small molecule
Drug Class	anticoagulants
Year of Approval	approved before 1982
Drug Categories	vasoprotectives
Drug Categories	thyroxine-binding globulin substrates
Drug Categories	sensory organs
Drug Categories	ophthalmologicals
Drug Categories	narrow therapeutic index drugs
Drug Categories	miscellaneous therapeutic agents
Drug Categories	heparins or heparinoids for topical use
Drug Categories	heparin and similars
Drug Categories	antivaricose therapy
Drug Categories	agents causing hyperkalemia

(3 More Sources)

Publications:

Chuang et al., 2001, Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin., J. Biol. Chem.
Schedin-Weiss et al., 2010, Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes., Arch. Biochem. Biophys.
Pappalardo et al., 2006, Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration., Perfusion
Sun et al., 2007, A fluorescent polymeric heparin sensor., Chemistry
Petitou et al., 1999, Synthesis of thrombin-inhibiting heparin mimetics without side effects., Nature
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Mirow et al., 2007, Plasma protein binding properties to immobilized heparin and heparin-albumin conjugate., Artif Organs
Gettins et al., 2009, Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement., FEBS Lett.
Sinosich et al., 1985, The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells., Tumour Biol.
Karnes JH et al., 2017, Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)., Pharmacotherapy
Koenig et al., 1998, Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents., J. Clin. Invest.
Gao et al., 2005, P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin., Mol. Cells
Nelson et al., 1993, Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation., Blood
Asberg et al., 2007, Inhibition of platelet receptors involved in neutrophil-platelet interaction in model cardiopulmonary bypass., Artif Organs
Simonis et al., 2007, Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition., Biochemistry
Maugeri et al., 2007, Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood., Thromb. Haemost.
Simonis et al., 2007, Affinity and kinetics of different heparins binding to P- and L-selectin., Semin. Thromb. Hemost.
Berry et al., 2006, Heparin localization and fine structure regulate Burkitt's lymphoma growth., Biochem. Biophys. Res. Commun.
Nisoli et al., 2000, Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion., Diabetes
Miyata et al., 1995, Interaction between casein kinase II and the 90-kDa stress protein, HSP90., Biochemistry
Patel et al., 2001, Chemokines have diverse abilities to form solid phase gradients., Clin. Immunol.
Randi et al., 1992, Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin., J. Biol. Chem.
Patey et al., 2006, Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases., J. Med. Chem.
Rezaie, 2000, Heparin-binding exosite of factor Xa., Trends Cardiovasc. Med.
Ignjatovic et al., 2007, Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?, Thromb. Res.
Rosenberg, 1985, Role of heparin and heparinlike molecules in thrombosis and atherosclerosis., Fed. Proc.
Van Iwaarden et al., 1994, Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides., Biochem. J.
Fath et al., 1998, Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma., J. Biol. Chem.
Walter et al., 1996, Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin., Arch. Biochem. Biophys.
Hansen et al., 2000, Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin., Thromb. Res.
Whinna et al., 1993, Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor., J. Protein Chem.
Park et al., 2001, Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence., Nature
Harenberg et al., 1985, Anticoagulant and lipolytic effects of a low molecular weight heparin fraction., Thromb. Res.
Eckel et al., 1988, Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation., Diabetes
Hallgren et al., 2004, Histidines are critical for heparin-dependent activation of mast cell tryptase., J. Immunol.
Bakillah et al., 1998, Lysine and arginine residues in the N-terminal 18% of apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein., Biochemistry
Krul et al., 1988, Regional specificities of monoclonal anti-human apolipoprotein B antibodies., J. Lipid Res.
Hansen et al., 1995, Identification of a homologous heparin binding peptide sequence present in fibronectin and the 70 kDa family of heat-shock proteins., Biochim. Biophys. Acta
Wojtecka-Lukasik et al., 1984, Effects of neutral proteases from human leukocytes on plasma fibronectin., Thromb. Res.
Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
Bellosta et al., 2001, Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis., Mol. Cell. Biol.
Vettor et al., 2000, Substrate competition and insulin action in animal models., Int. J. Obes. Relat. Metab. Disord.
Gambetti et al., 2005, Interaction with heparin protects tissue transglutaminase against inactivation by heating and by proteolysis., Biochimie
Kolset et al., 1996, Serglycin-binding proteins in activated macrophages and platelets., J. Leukoc. Biol.
Okano et al., 2001, Biochemical characterization of cholesterol-3-sulfate as the sole effector for the phosphorylation of HMG1 by casein kinase I in vitro., Biochem. Biophys. Res. Commun.
Nakamura et al., 1995, Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery., J. Clin. Invest.
Robinson CJ et al., 2005, Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes., J Biol Chem
Loo BM et al., 2001, Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4., J Biol Chem
Rose K et al., 2007, Basic fibroblast growth factor: lysine 134 is essential for its neuroprotective activity., Neurochem Int
Visentin GP et al., 1994, Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells., J Clin Invest
Greinacher A et al., 2010, Heparin-induced thrombocytopenia., Hamostaseologie
Sakata H et al., 1997, Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling., J Biol Chem
Harmer NJ et al., 2004, The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity., Biochemistry
Ibrahimi OA et al., 2004, Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly., Biochemistry

HEPARIN SERPINC1

Interaction Types & Directionality:

potentiator

activator (activating)

Interaction Info:

Trial Name heparin

Novel drug target Established target

Trial Name heparin, oral, liquid

Publications:

Chuang et al., 2001, Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin., J. Biol. Chem.

Schedin-Weiss et al., 2010, Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes., Arch. Biochem. Biophys.

Pappalardo et al., 2006, Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration., Perfusion

HEPARIN F10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name heparin

Novel drug target Established target

Trial Name heparin, oral, liquid

Publications:

Patey et al., 2006, Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases., J. Med. Chem.

Rezaie, 2000, Heparin-binding exosite of factor Xa., Trends Cardiovasc. Med.

Ignjatovic et al., 2007, Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?, Thromb. Res.

HEPARIN SELP

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Koenig et al., 1998, Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents., J. Clin. Invest.

Gao et al., 2005, P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin., Mol. Cells

Nelson et al., 1993, Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation., Blood

HEPARIN HPSE

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name M118

Novel drug target Established target

Publications:
HEPARIN F2

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name octaparine, AVE-5026

Novel drug target Established target

Publications:
HEPARIN TFPI2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sinosich et al., 1985, The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells., Tumour Biol.
HEPARIN HLA-DRB3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Karnes JH et al., 2017, Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)., Pharmacotherapy
HEPARIN PIK3CG

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Berry et al., 2006, Heparin localization and fine structure regulate Burkitt's lymphoma growth., Biochem. Biophys. Res. Commun.

HEPARIN UCP2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Nisoli et al., 2000, Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion., Diabetes

HEPARIN CSNK2A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Miyata et al., 1995, Interaction between casein kinase II and the 90-kDa stress protein, HSP90., Biochemistry
HEPARIN CCL21

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Patel et al., 2001, Chemokines have diverse abilities to form solid phase gradients., Clin. Immunol.

HEPARIN VWF

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Randi et al., 1992, Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin., J. Biol. Chem.

HEPARIN SFTPA1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Van Iwaarden et al., 1994, Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides., Biochem. J.

HEPARIN SLPI

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Fath et al., 1998, Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma., J. Biol. Chem.

Walter et al., 1996, Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin., Arch. Biochem. Biophys.

HEPARIN TFPI

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hansen et al., 2000, Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin., Thromb. Res.
HEPARIN SERPINA5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Whinna et al., 1993, Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor., J. Protein Chem.
HEPARIN SDC1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Park et al., 2001, Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence., Nature

HEPARIN LIPC

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Harenberg et al., 1985, Anticoagulant and lipolytic effects of a low molecular weight heparin fraction., Thromb. Res.

Eckel et al., 1988, Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation., Diabetes

HEPARIN TPSB2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hallgren et al., 2004, Histidines are critical for heparin-dependent activation of mast cell tryptase., J. Immunol.

HEPARIN APOB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Bakillah et al., 1998, Lysine and arginine residues in the N-terminal 18% of apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein., Biochemistry

Krul et al., 1988, Regional specificities of monoclonal anti-human apolipoprotein B antibodies., J. Lipid Res.

HEPARIN HSPA4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hansen et al., 1995, Identification of a homologous heparin binding peptide sequence present in fibronectin and the 70 kDa family of heat-shock proteins., Biochim. Biophys. Acta
HEPARIN NR5A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wojtecka-Lukasik et al., 1984, Effects of neutral proteases from human leukocytes on plasma fibronectin., Thromb. Res.
HEPARIN FCGR3B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
HEPARIN FGF4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Bellosta et al., 2001, Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis., Mol. Cell. Biol.
HEPARIN SLC2A4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Vettor et al., 2000, Substrate competition and insulin action in animal models., Int. J. Obes. Relat. Metab. Disord.
HEPARIN TGM2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gambetti et al., 2005, Interaction with heparin protects tissue transglutaminase against inactivation by heating and by proteolysis., Biochimie
HEPARIN SRGN

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kolset et al., 1996, Serglycin-binding proteins in activated macrophages and platelets., J. Leukoc. Biol.
HEPARIN CSNK1A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Okano et al., 2001, Biochemical characterization of cholesterol-3-sulfate as the sole effector for the phosphorylation of HMG1 by casein kinase I in vitro., Biochem. Biophys. Res. Commun.
HEPARIN FCGR3A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
HEPARIN PLA2G2A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Nakamura et al., 1995, Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery., J. Clin. Invest.

HEPARIN FGFR2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Robinson CJ et al., 2005, Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes., J Biol Chem

HEPARIN FGFR4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Loo BM et al., 2001, Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4., J Biol Chem
HEPARIN FGF2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Rose K et al., 2007, Basic fibroblast growth factor: lysine 134 is essential for its neuroprotective activity., Neurochem Int

HEPARIN FGF1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Robinson CJ et al., 2005, Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes., J Biol Chem

HEPARIN PF4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Visentin GP et al., 1994, Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells., J Clin Invest

Greinacher A et al., 2010, Heparin-induced thrombocytopenia., Hamostaseologie

HEPARIN HGF

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakata H et al., 1997, Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling., J Biol Chem

HEPARIN FGF19

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Harmer NJ et al., 2004, The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity., Biochemistry

HEPARIN FGFR1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ibrahimi OA et al., 2004, Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly., Biochemistry

DrugBank: DB01109

Version: 5.1.7

Alternate Names:

HEPARIN DrugBank Drug Name

9005-49-6 CAS Number

Calcilean Drug Brand

Drug Info:

Drug Groups approved

Drug Type small molecule

Drug Groups investigational

Publications:

Patey et al., 2006, Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases., J. Med. Chem.

Ignjatovic et al., 2007, Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?, Thromb. Res.

Rosenberg, 1985, Role of heparin and heparinlike molecules in thrombosis and atherosclerosis., Fed. Proc.

TEND: HEPARIN
- Version: 01-August-2011
Alternate Names:

HEPARIN Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class anticoagulants

Publications:
TdgClinicalTrial: HEPARIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications anticoagulant

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: HEPARIN

Version: 14-September-2017

Alternate Names:

C539 NCI drug code

Drug Info:

Publications:

Sinosich et al., 1985, The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells., Tumour Biol.

Park et al., 2001, Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence., Nature

Bellosta et al., 2001, Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis., Mol. Cell. Biol.

PharmGKB: heparin
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Karnes JH et al., 2017, Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)., Pharmacotherapy
GuideToPharmacologyInteractions: 178101031
- Version: 20-July-2020
Alternate Names:

HEPARIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1909300
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	heparin
Novel drug target	Established target
Trial Name	heparin, oral, liquid

Trial Name	octaparine, AVE-5026
Novel drug target	Established target

HEPARIN	DrugBank Drug Name
9005-49-6	CAS Number
Calcilean	Drug Brand

HEPARIN Drug Record

HEPARIN chembl:CHEMBL1909300

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: potentiator activator (activating)

Interaction Info: Trial Name heparin Novel drug target Established target Trial Name heparin, oral, liquid

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name heparin Novel drug target Established target Trial Name heparin, oral, liquid

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name M118 Novel drug target Established target

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name octaparine, AVE-5026 Novel drug target Established target

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sinosich et al., 1985, The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells., Tumour Biol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Karnes JH et al., 2017, Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)., Pharmacotherapy

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Berry et al., 2006, Heparin localization and fine structure regulate Burkitt's lymphoma growth., Biochem. Biophys. Res. Commun.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Nisoli et al., 2000, Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion., Diabetes

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Miyata et al., 1995, Interaction between casein kinase II and the 90-kDa stress protein, HSP90., Biochemistry

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Patel et al., 2001, Chemokines have diverse abilities to form solid phase gradients., Clin. Immunol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Randi et al., 1992, Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin., J. Biol. Chem.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Van Iwaarden et al., 1994, Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides., Biochem. J.

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Hansen et al., 2000, Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin., Thromb. Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Whinna et al., 1993, Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor., J. Protein Chem.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Park et al., 2001, Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence., Nature

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Harenberg et al., 1985, Anticoagulant and lipolytic effects of a low molecular weight heparin fraction., Thromb. Res. Eckel et al., 1988, Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation., Diabetes

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Hallgren et al., 2004, Histidines are critical for heparin-dependent activation of mast cell tryptase., J. Immunol.

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Hansen et al., 1995, Identification of a homologous heparin binding peptide sequence present in fibronectin and the 70 kDa family of heat-shock proteins., Biochim. Biophys. Acta

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wojtecka-Lukasik et al., 1984, Effects of neutral proteases from human leukocytes on plasma fibronectin., Thromb. Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Bellosta et al., 2001, Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis., Mol. Cell. Biol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Vettor et al., 2000, Substrate competition and insulin action in animal models., Int. J. Obes. Relat. Metab. Disord.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gambetti et al., 2005, Interaction with heparin protects tissue transglutaminase against inactivation by heating and by proteolysis., Biochimie

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

potentiator

activator (activating)

Interaction Info:

Trial Name heparin

Novel drug target Established target

Trial Name heparin, oral, liquid

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name heparin

Novel drug target Established target

Trial Name heparin, oral, liquid

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name M118

Novel drug target Established target

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name octaparine, AVE-5026

Novel drug target Established target

Interaction Types & Directionality:

n/a

Publications:

Sinosich et al., 1985, The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells., Tumour Biol.

Interaction Types & Directionality:

n/a

Publications:

Karnes JH et al., 2017, Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)., Pharmacotherapy

Interaction Types & Directionality:

n/a

Publications:

Berry et al., 2006, Heparin localization and fine structure regulate Burkitt's lymphoma growth., Biochem. Biophys. Res. Commun.

Interaction Types & Directionality:

n/a

Publications:

Nisoli et al., 2000, Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion., Diabetes

Interaction Types & Directionality:

n/a

Publications:

Miyata et al., 1995, Interaction between casein kinase II and the 90-kDa stress protein, HSP90., Biochemistry

Interaction Types & Directionality:

n/a

Publications:

Patel et al., 2001, Chemokines have diverse abilities to form solid phase gradients., Clin. Immunol.

Interaction Types & Directionality:

n/a

Publications:

Randi et al., 1992, Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin., J. Biol. Chem.

Interaction Types & Directionality:

n/a

Publications:

Van Iwaarden et al., 1994, Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides., Biochem. J.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Hansen et al., 2000, Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin., Thromb. Res.

Interaction Types & Directionality:

n/a

Publications:

Whinna et al., 1993, Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor., J. Protein Chem.

Interaction Types & Directionality:

n/a

Publications:

Park et al., 2001, Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence., Nature

Interaction Types & Directionality:

n/a

Publications:

Harenberg et al., 1985, Anticoagulant and lipolytic effects of a low molecular weight heparin fraction., Thromb. Res.

Eckel et al., 1988, Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation., Diabetes

Interaction Types & Directionality:

n/a

Publications:

Hallgren et al., 2004, Histidines are critical for heparin-dependent activation of mast cell tryptase., J. Immunol.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Hansen et al., 1995, Identification of a homologous heparin binding peptide sequence present in fibronectin and the 70 kDa family of heat-shock proteins., Biochim. Biophys. Acta

Interaction Types & Directionality:

n/a

Publications:

Wojtecka-Lukasik et al., 1984, Effects of neutral proteases from human leukocytes on plasma fibronectin., Thromb. Res.

Interaction Types & Directionality:

n/a

Publications:

Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)

Interaction Types & Directionality:

n/a

Publications:

Bellosta et al., 2001, Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis., Mol. Cell. Biol.

Interaction Types & Directionality:

n/a

Publications:

Vettor et al., 2000, Substrate competition and insulin action in animal models., Int. J. Obes. Relat. Metab. Disord.

Interaction Types & Directionality:

n/a

Publications:

Gambetti et al., 2005, Interaction with heparin protects tissue transglutaminase against inactivation by heating and by proteolysis., Biochimie

Interaction Types & Directionality:

n/a

Publications:

Kolset et al., 1996, Serglycin-binding proteins in activated macrophages and platelets., J. Leukoc. Biol.

Interaction Types & Directionality:

n/a

Publications:

Okano et al., 2001, Biochemical characterization of cholesterol-3-sulfate as the sole effector for the phosphorylation of HMG1 by casein kinase I in vitro., Biochem. Biophys. Res. Commun.

Interaction Types & Directionality:

n/a

Publications:

Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)

Interaction Types & Directionality:

n/a

Publications:

Nakamura et al., 1995, Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery., J. Clin. Invest.

Interaction Types & Directionality:

n/a

Publications:

Robinson CJ et al., 2005, Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes., J Biol Chem

Interaction Types & Directionality:

n/a

Publications:

Loo BM et al., 2001, Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4., J Biol Chem

Interaction Types & Directionality:

n/a

Publications:

Rose K et al., 2007, Basic fibroblast growth factor: lysine 134 is essential for its neuroprotective activity., Neurochem Int

Interaction Types & Directionality:

n/a

Publications:

Robinson CJ et al., 2005, Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes., J Biol Chem

Interaction Types & Directionality:

n/a

Publications:

Visentin GP et al., 1994, Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells., J Clin Invest

Greinacher A et al., 2010, Heparin-induced thrombocytopenia., Hamostaseologie

Interaction Types & Directionality:

n/a

Publications:

Sakata H et al., 1997, Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling., J Biol Chem